StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Halozyme Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $102.37M, up 43.7% year over year. For fiscal 2025 it was $81.49M, up 3.1% from the year before. Over ten years it grew -1.3% a year on average. The highest annual figure on record is $150.84M in fiscal 2016.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$81.49M+3.1%
FY2024Dec 31, 2024$79.05M+3.5%
FY2023Dec 31, 2023$76.36M+14.6%
FY2022Dec 31, 2022$66.61M+86.7%
FY2021Dec 31, 2021$35.67M+4.2%
FY2020Dec 31, 2020$34.24M-75.7%
FY2019Dec 31, 2019$140.80M-6.3%
FY2018Dec 31, 2018$150.25M-0.3%
FY2017Dec 31, 2017$150.64M-0.1%
FY2016Dec 31, 2016$150.84M+61.8%
FY2015Dec 31, 2015$93.24M+17.0%
FY2014Dec 31, 2014$79.70M-17.5%
FY2013Dec 31, 2013$96.64M+38.0%
FY2012Dec 31, 2012$70.04M+21.7%
FY2011Dec 31, 2011$57.56M+11.2%
FY2010Dec 31, 2010$51.77M-8.6%
FY2009Dec 31, 2009$56.61M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$27.66M+57.7%
Q1 FY2026Mar 31, 2026$25.56M+72.7%
Q4 FY2025Dec 31, 2025$31.90M+56.0%
Q3 FY2025Sep 30, 2025$17.25M-6.5%
Q2 FY2025Jun 30, 2025$17.54M-16.6%
Q1 FY2025Mar 31, 2025$14.80M-22.6%
Q4 FY2024Dec 31, 2024$20.44M-4.2%
Q3 FY2024Sep 30, 2024$18.46M+6.6%
Q2 FY2024Jun 30, 2024$21.04M+6.6%
Q1 FY2024Mar 31, 2024$19.11M+6.3%
Q4 FY2023Dec 31, 2023$21.34M-5.5%
Q3 FY2023Sep 30, 2023$17.32M+3.7%
Q2 FY2023Jun 30, 2023$19.73M+27.4%
Q1 FY2023Mar 31, 2023$17.98M+51.7%
Q4 FY2022Dec 31, 2022$22.57M+123.2%
Q3 FY2022Sep 30, 2022$16.71M+96.9%
Q2 FY2022Jun 30, 2022$15.48M+91.9%
Q1 FY2022Mar 31, 2022$11.85M+31.6%
Q4 FY2021Dec 31, 2021$10.11M+37.0%
Q3 FY2021Sep 30, 2021$8.49M+9.5%
Q2 FY2021Jun 30, 2021$8.07M-9.9%
Q1 FY2021Mar 31, 2021$9.01M-11.3%
Q4 FY2020Dec 31, 2020$7.38M-83.6%
Q3 FY2020Sep 30, 2020$7.75M-74.6%
Q2 FY2020Jun 30, 2020$8.95M-73.6%
Q1 FY2020Mar 31, 2020$10.16M-67.6%
Q4 FY2019Dec 31, 2019$45.11M+23.1%
Q3 FY2019Sep 30, 2019$30.46M-14.3%
Q2 FY2019Jun 30, 2019$33.91M-15.4%
Q1 FY2019Mar 31, 2019$31.33M-17.5%
Q4 FY2018Dec 31, 2018$36.65M-11.4%
Q3 FY2018Sep 30, 2018$35.54M+4.6%
Q2 FY2018Jun 30, 2018$40.09M+4.6%
Q1 FY2018Mar 31, 2018$37.98M+2.8%
Q4 FY2017Dec 31, 2017$41.38M+0.1%
Q3 FY2017Sep 30, 2017$33.99M+0.4%
Q2 FY2017Jun 30, 2017$38.34M–
Q1 FY2017Mar 31, 2017$36.94M–
Q4 FY2016Dec 31, 2016$41.35M–
Q3 FY2016Sep 30, 2016$33.86M–

More Halozyme Therapeutics figures

See a number that looks wrong?